Clinical trials: ADHD - Attention Deficit Disorder With Hyperactivity
- Condition ADHD - Attention Deficit Disorder With Hyperactivity
- Funder type Industry (pharma, biotech, devices)
Attention-Deficit/Hyperactivity Disorder
Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)
The purpose of this study is to investigate the treatment effectiveness of Adhansia XR at month-2 after initiation, and the effectiveness of Adhansia XR overall and when compared with the active comparator group (Concerta) over…
- Trial name
- RE-DAX (NCT04507204)
- Testing
- Adhansia XR, Concerta
- Where
- 35 sites in United States
- Volunteers
- 267 people
- Sponsor
- Purdue Pharma LP
Attention-Deficit/Hyperactivity Disorder
Long Term Safety and Tolerability Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
The objective of this study is to evaluate the long-term effects and tolerability of ABT-089 in adults with Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT00686933
- Testing
- ABT-089
- Where
- 12 sites in United States
- Volunteers
- 117 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Attention-Deficit/Hyperactivity Disorder (ADHD)
Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.
This study will evaluate the efficacy and safety of Dex-Methylphenidate Extended Release 30 mg compared to 20 mg in pediatric patients ages 6-12 with Attention-Deficit Hyperactivity Disorder (ADHD) in a 12-hour laboratory…
- Trial name
- NCT00776009
- Testing
- Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR)
- Where
- 8 sites in United States
- Volunteers
- 165 people
- Sponsor
- Novartis Pharmaceuticals